KEGG   DRUG: Pembrolizumab and berahyaluronidase alfa
Entry
D13168            Mixture   Drug                                   
Name
Pembrolizumab and berahyaluronidase alfa;
Pembrolizumab and berahyaluronidase alfa-pmph;
Keytruda qlex (TN)
Component
Pembrolizumab [DR:D10574], Berahyaluronidase alfa [DR:D12911]
Remark
ATC code: L01FF02
Efficacy
Antineoplastic
  Disease
Melanoma [DS:H00038]
Non-small cell lung cancer (no EGFR or ALK genomic tumor) [DS:H00014]
Non-small cell lung cancer (expressing PD-L1) [DS:H00014]
Malignant pleural mesothelioma [DS:H00015]
Head and neck squamous cell cancer (express PD-L1) [DS:H02420]
Urothelial cancer [DS:H00022]
Colorectal cancer (MSI-H or dMMR) [DS:H00020]
Gastric cancer (express PD-L1, HER2-positive) [DS:H00018]
Esophageal cancer (express PD-L1) [DS:H00017]
Cervical cancer (express PD-L1) [DS:H00030]
Hepatocellular carcinoma [DS:H00048]
Biliary tract cancer [DS:H00046 H00047]
Merkel cell carcinoma [DS:H01555]
Renal cell carcinoma [DS:H00021]
Endometrial cancer [DS:H00026]
Endometrial cancer (MSI-H or dMMR) [DS:H00026]
Cutaneous squamous cell carcinoma [DS:H00040]
Breast cancer (triple negative, express PD-L1) [DS:H00031]
Target
PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  Pathway
hsa04514  Cell adhesion molecules
hsa04660  T cell receptor signaling pathway
hsa05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FF PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
     L01FF02 Pembrolizumab
      D13168  Pembrolizumab and berahyaluronidase alfa
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDCD1 (PD1, CD279)
     D13168  Pembrolizumab and berahyaluronidase alfa
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D13168
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D13168
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system